PFE | Weekly | Haru Insights

The European Medicines Agency’s CHMP positive opinion in October 2026 for Tukysa as a first-line therapy in combination with Herceptin and Perjeta for HER2-positive breast cancer marks a pivotal regulatory milestone with near-term commercial implications for Pfizer’s oncology franchise.
The upcoming Phase 3 data readout from the DAYBreak CLL-306 trial (bexobrutideg vs. pirtobrutinib) represents a high-stakes catalyst that could redefine Pfizer’s leadership in the BTK inhibitor space and directly impact its oncology growth trajectory.

Pfizer’s leap into next-generation modalities like PROTACs is now a reality, as veppanu (vepdegestrant) nears becoming the first FDA-approved PROTAC therapy—proof that PFE’s long-term R&D ambitions are translating into groundbreaking medicine.
The EMA’s positive opinion on Tukysa’s expanded indication signals not just regulatory validation but a strong commercial runway, reinforcing PFE’s oncology momentum amid legacy patent cliffs.
LB6V, the first-ever Lyme disease vaccine candidate, could redefine infectious disease prevention and deliver transformative public health and revenue upside—positioning PFE at the forefront of a high-need, high-reward market.
PF-07872412, PFE’s 25-valent pneumococcal vaccine, shows potential to outperform PREVNAR 20 in infants—signaling a major leap in pediatric immunization and a clear path to market leadership in respiratory vaccines.
Pfizer’s expanding oncology footprint is being anchored by multiple high-potential franchises like Padcev and Lorbrena, providing a credible, diversified buffer against revenue stagnation from older blockbusters.

Pfizer Inc. (PFE)[Tv]